Ontak gains full US approval for CD25-positive cutaneous T-cell lymphoma
This article was originally published in Scrip
Executive Summary
Eisaihas received full US FDAapproval for its fusion protein Ontak (denileukin diftitox) for the orphan indication of persistent or recurrent CD25-positive cutaneous T-cell lymphoma (CTCL), following a Phase III trial which confirmed response rate benefits in such patients.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports